<i>Lactobacillus reuteri <scp>DSM</scp> 17938</i> and a placebo both significantly reduced symptoms in children with functional abdominal pain

Maragkoudaki, Maria; Chouliaras, Giorgos; Orel, Rok; Horvath, Andrea; Szajewska, Hania; Papadopoulou, Alexandra

doi:10.1111/apa.13992

Cited by 39 publications

(32 citation statements)

References 28 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although meta-analyses of paediatric trials have been performed, only few studies exist and with similar caveats to the adult meta-analyses 158,159 . Among five RCTs investigating children with FAP-NOS, the probiotic Lactobacillus reuteri DSM 1793 improved abdominal pain in three studies [160][161][162] , reduced functional disability but not abdominal pain in one study 163 , and was not superior to placebo in another 164 , although the methods of pain evaluation were different across studies. In children with IBS, two studies found that Lactobacillus rhamnosus GG was effective in reducing abdominal pain symptoms 165,166 and one study reported no improvement in abdominal pain but an improvement in perceived abdominal distention; measures of pain differed yet again among the different studies.…”

Section: Probioticsmentioning

confidence: 99%

Paediatric functional abdominal pain disorders

Thapar

Benninga

Crowell

et al. 2020

Nat Rev Dis Primers

110

119

View full text Add to dashboard Cite

show abstract

Section: Probioticsmentioning

confidence: 99%

Paediatric functional abdominal pain disorders

Thapar

Benninga

Crowell

et al. 2020

Nat Rev Dis Primers

110

119

View full text Add to dashboard Cite

show abstract

“…Jadrešin O et al [ 114 ] demonstrated that administration of L. reuteri DSM 17938 is associated with a reduction of the intensity and frequency of pain in population study including patients with FAP and IBS. Maragkoudaki M et al [ 115 ] found that in a paediatric cohort L. reuteri DSM 17938, at a dose of 2 X 10 8 CFU was not different from placebo in reducing the frequency and intensity of the abdominal pain episodes. By contrast in the intervention arm a reduction in pain relieving drugs was registered, even if not statistically significant.…”

Section: Resultsmentioning

confidence: 99%

Probiotics’ efficacy in paediatric diseases: which is the evidence? A critical review on behalf of the Italian Society of Pediatrics

et al. 2020

View full text Add to dashboard Cite

During the last decade several paediatric studies have been published with different possible indications for probiotics, leading to a global increase of probiotics’ market. Nevertheless, different study designs, multiple single/combined strains and small sample size still leave many uncertainties regarding their efficacy. In addition, different regulatory and quality control issues make still very difficult the interpretation of the clinical data. The objective of this review is to critically summarise the current evidence on probiotics’ efficacy and safety on a different number of pathologies, including necrotizing enterocolitis, acute infectious diarrhoea, allergic diseases and functional gastrointestinal disorders in order to guide paediatric healthcare professionals on using evidence-based probiotics’ strains. To identify relevant data, literature searches were performed including Medline-PubMed, the Cochrane Library and EMBASE databases. Considering probiotics strain-specific effects, the main focus was on individual probiotic strains and not on probiotics in general.

show abstract

“…Jadrešin et al 137 demonstrated a reduction in days with pain and pain severity in children with IBS and FAP. In studies focused specifically on FAP, Romano et al 138 reported reduced pain severity and Weizman et al 139 and Maragkoudaki et al 140 both reported reduced pain severity and frequency in those treated with the probiotic compared with placebo.…”

Section: Functional Gi Disordersmentioning

confidence: 99%

The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders

Shin

Preidis

Shulman

et al. 2019

Clinical Gastroenterology and Hepatology

127

View full text Add to dashboard Cite

The importance of gut microbiota in gastrointestinal (GI) physiology was well described, but our ability to study gut microbial ecosystems in their entirety was limited by culture-based methods prior to the sequencing revolution. The advent of high-throughput sequencing opened new avenues, allowing us to study gut microbial communities as an aggregate, independent of our ability to culture individual microbes. Early studies focused on association of changes in gut microbiota with different disease states, which was necessary to identify a potential role for microbes and generate novel hypotheses. Over the past few years the field has moved beyond associations to better understand the mechanistic implications of the microbiome in the pathophysiology of complex diseases. This movement also has resulted in a shift in our focus toward therapeutic strategies, which rely on better understanding the mediators of gut microbiota-host cross-talk. It is not surprising the gut microbiome has been implicated in the pathogenesis of functional gastrointestinal disorders given its role in modulating physiological processes such as immune development, GI motility and secretion, epithelial barrier integrity, and brain-gut communication. In this review, we focus on the current state of knowledge and future directions in microbiome research as it pertains to functional gastrointestinal disorders. We summarize the factors that help shape the gut microbiome in human beings. We discuss data from animal models and human studies to highlight existing paradigms regarding the mechanisms underlying microbiota-mediated alterations in physiological processes and their relevance in human interventions. While translation of microbiome science is still in its infancy, the outlook is optimistic and we are advancing in the right direction toward precise mechanism-based microbiota therapies.

show abstract

Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain

Abstract: Both L. reuteri and the placebo were effective in alleviating pain in children with FAP, but only L. reuteri improved the child's and family's normal activities.

Cited by 39 publications

References 28 publications

Paediatric functional abdominal pain disorders

Paediatric functional abdominal pain disorders

Probiotics’ efficacy in paediatric diseases: which is the evidence? A critical review on behalf of the Italian Society of Pediatrics

The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders

Contact Info

Product

Resources

About